Coya Therapeutics advances COYA 302 as FDA fast track status raises clinical expectations
Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.
Pharma & Biotech
Pharma & Biotech
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.